Celgene Corporation (CELG) Shares Bought by YHB Investment Advisors Inc.
YHB Investment Advisors Inc. lifted its position in Celgene Corporation (NASDAQ:CELG) by 13.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 83,561 shares of the biopharmaceutical company’s stock after purchasing an additional 9,886 shares during the period. Celgene Corporation accounts for about 1.9% of YHB Investment Advisors Inc.’s investment portfolio, making the stock its 12th biggest position. YHB Investment Advisors Inc.’s holdings in Celgene Corporation were worth $10,852,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Harel Insurance Investments & Financial Services Ltd. bought a new stake in Celgene Corporation during the 1st quarter valued at $118,000. Acropolis Investment Management LLC purchased a new stake in Celgene Corporation in the second quarter worth about $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Celgene Corporation by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares during the period. Oakworth Capital Inc. lifted its stake in Celgene Corporation by 11.7% in the second quarter. Oakworth Capital Inc. now owns 1,216 shares of the biopharmaceutical company’s stock worth $158,000 after acquiring an additional 127 shares during the period. Finally, WealthTrust Arizona LLC lifted its stake in Celgene Corporation by 5.2% in the second quarter. WealthTrust Arizona LLC now owns 1,276 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 63 shares during the period. Hedge funds and other institutional investors own 79.36% of the company’s stock.
Celgene Corporation (NASDAQ:CELG) opened at 146.08 on Wednesday. Celgene Corporation has a 52 week low of $96.93 and a 52 week high of $147.17. The stock has a 50 day moving average price of $138.30 and a 200 day moving average price of $129.24. The stock has a market cap of $114.29 billion, a PE ratio of 45.24 and a beta of 1.88.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm had revenue of $3.27 billion during the quarter, compared to analysts’ expectations of $3.23 billion. During the same period in the prior year, the company earned $1.44 EPS. The firm’s revenue was up 18.7% on a year-over-year basis. On average, equities analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.
A number of research analysts have recently issued reports on the company. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $175.00 price target on shares of Celgene Corporation in a report on Wednesday, August 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a research note on Tuesday, September 26th. Vetr upgraded shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a research note on Wednesday, August 16th. SunTrust Banks, Inc. reiterated a “buy” rating and set a $150.00 price objective on shares of Celgene Corporation in a research note on Friday, July 14th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $160.00 target price on shares of Celgene Corporation in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the company. Celgene Corporation presently has an average rating of “Buy” and a consensus target price of $150.54.
In related news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $130.52, for a total value of $2,415,403.12. Following the transaction, the director now directly owns 69,424 shares in the company, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders sold 46,233 shares of company stock worth $6,268,259 over the last three months. 0.95% of the stock is currently owned by corporate insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.